Get the Stockscreener App
2.02
15.06%
0.26
Pulmonx Corp stock is traded at $2.02, with a volume of 1.89M.
It is up +15.06% in the last 24 hours and up +25.00% over the past month.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
See More
Previous Close:
$1.76
Open:
$1.76
24h Volume:
1.89M
Relative Volume:
0.82
Market Cap:
$82.71M
Revenue:
$68.68M
Net Income/Loss:
$-60.84M
P/E Ratio:
-1.2625
EPS:
-1.6
Net Cash Flow:
$-38.42M
1W Performance:
+23.48%
1M Performance:
+25.00%
6M Performance:
-58.07%
1Y Performance:
-67.60%
1-Day Range:
$1.74
$2.10
1-Week Range:
$1.56
$2.89
52-Week Range:
$1.47
$9.37
Pulmonx Corp Stock (LUNG) Company Profile
Name
Pulmonx Corp
Sector
Industry
Phone
650-364-0400
Address
700 CHESAPEAKE DRIVE, REDWOOD CITY
Compare LUNG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
2.0299 | 71.71M | 68.68M | -60.84M | -38.42M | -1.60 |
|
ABT
Abbott Laboratories
|
123.69 | 216.79B | 43.84B | 13.94B | 6.78B | 7.9979 |
|
BSX
Boston Scientific Corp
|
101.05 | 149.02B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
357.75 | 141.06B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
91.04 | 116.68B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.01 | 49.01B | 5.69B | 1.41B | 577.90M | 6.9828 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-10-25 | Initiated | D. Boral Capital | Buy |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-04-24 | Initiated | Lake Street | Buy |
| Feb-23-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-05-23 | Initiated | Craig Hallum | Buy |
| Feb-27-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-03-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Dec-08-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-01-21 | Initiated | Citigroup | Buy |
| Mar-25-21 | Initiated | Piper Sandler | Neutral |
| Mar-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-26-20 | Initiated | BofA Securities | Buy |
| Oct-26-20 | Initiated | Canaccord Genuity | Buy |
| Oct-26-20 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-26-20 | Initiated | Stifel | Buy |
| Oct-26-20 | Initiated | Wells Fargo | Equal Weight |
View All
Pulmonx Corp Stock (LUNG) Latest News
Is Pulmonx Corporation (LUNG) One of the Best Stocks Under $3 to Invest In? - Insider Monkey
Is Pulmonx Corporation reversing from oversold territoryWeekly Trade Report & Weekly High Potential Stock Alerts - newser.com
Historical volatility pattern of Pulmonx Corporation visualizedChart Signals & High Accuracy Swing Trade Signals - newser.com
Why Pulmonx Corporation stock remains on watchlistsJuly 2025 Sentiment & Accurate Technical Buy Alerts - newser.com
Is this a good reentry point in Pulmonx CorporationJuly 2025 Snapshot & Daily Profit Focused Screening - newser.com
Pulmonx (NASDAQ:LUNG) Given New $14.00 Price Target at D. Boral Capital - MarketBeat
Pulmonx (LUNG) Anticipates Q3 Revenue of $21.5 Million - GuruFocus
What hedge fund activity signals for Pulmonx Corporation stockRecession Risk & Daily Profit Maximizing Tips - newser.com
Tick level data insight on Pulmonx Corporation volatilityMarket Activity Summary & Entry Point Strategy Guides - newser.com
Lake Street Lowers Price Target for Pulmonx (LUNG) Amidst Mainta - GuruFocus
LUNG’s Surprise Revenue Surge: Key Factors - StocksToTrade
Pulmonx brings back former CEO amid leadership shakeup - Investing.com India
Pulmonx Corp (LUNG) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Pulmonx Corp (LUNG) Q3 2025 Earnings Report Preview: What To Exp - GuruFocus
Canaccord Genuity reiterates Buy rating on Pulmonx stock amid leadership changes - Investing.com Nigeria
Using data filters to optimize entry into Pulmonx CorporationQuarterly Profit Report & Fast Entry and Exit Trade Plans - newser.com
Using Python tools to backtest Pulmonx Corporation strategiesDip Buying & Fast Gain Stock Tips - newser.com
D. Boral Capital Maintains Pulmonx (LUNG) Buy Recommendation - Nasdaq
Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Analyst Lowers Price Target for Pulmonx (LUNG) While Maintaining Buy Rating | LUNG Stock News - GuruFocus
Pulmonx brings back former CEO amid leadership shakeup By Investing.com - Investing.com Australia
Will Pulmonx Corporation stock maintain momentum in 2025Weekly Gains Report & Risk Adjusted Buy/Sell Alerts - newser.com
Technical signs of recovery in Pulmonx CorporationWeekly Investment Summary & Risk Adjusted Buy/Sell Alerts - newser.com
How Pulmonx Corporation stock compares to market leaders2025 Breakouts & Breakdowns & High Conviction Trade Alerts - newser.com
Healthcare Rally: Pulmonx, UHS, And X4 Lead After-Hours Gains Amid Strategic Updates - Nasdaq
What catalysts could drive Pulmonx Corporation stock higherMarket Volume Summary & Fast Exit/Entry Strategy Plans - newser.com
Visualizing Pulmonx Corporation stock with heatmaps2025 Market Outlook & Safe Capital Growth Tips - newser.com
Pulmonx Corp (LUNG) Q3 2025 Earnings: Revenue Surpasses Estimates at $21.5 Million - GuruFocus
LUNG to Discuss Q3 2025 Results and Annual Outlook in November C - GuruFocus
Pulmonx Announces Leadership Changes with New CEO - TipRanks
Pulmonx announces management transition and preliminary third quarter 2025 revenue reschedules third quarter 2025 earnings call to November 12, 2025 - MarketScreener
Pulmonx Announces Management Transition And Preliminary Third Quarter 2025 Revenue Reschedules Third Quarter 2025 Earnings Call To November 12, 2025 - TradingView
Pulmonx Corporation Announces Leadership Transition and Preliminary Third Quarter 2025 Revenue Estimates - Quiver Quantitative
Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025 - The Manila Times
Pulmonx Corporation Announces CEO Changes, Effective October 27, 2025 - MarketScreener
Pulmonx (Nasdaq: LUNG) reappoints Glen French as CEO; preliminary Q3 revenue ~$21.5M - Stock Titan
Real time social sentiment graph for Pulmonx CorporationPortfolio Growth Summary & High Conviction Buy Zone Picks - newser.com
Can Pulmonx Corporation stock withstand economic slowdownTrade Analysis Report & AI Powered Buy/Sell Recommendations - newser.com
Pulmonx Corp Stock (LUNG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pulmonx Corp Stock (LUNG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Joshi Mehul | Chief Financial Officer & PAO |
Sep 02 '25 |
Sale |
1.60 |
7,936 |
12,698 |
208,489 |
| Rose Geoffrey Beran | CHIEF COMMERCIAL OFFICER |
Sep 02 '25 |
Sale |
1.60 |
6,543 |
10,469 |
379,788 |
| Lehman David Aaron | GENERAL COUNSEL |
Sep 02 '25 |
Sale |
1.60 |
9,769 |
15,630 |
263,270 |
| Ferrari Richard | Director |
Jun 12 '25 |
Sale |
3.16 |
8,000 |
25,280 |
87,024 |
1.22%
13.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):